Table 2.

FLT3 inhibitors in clinical trial for AML.

1° Generation
Inhibitor	Sorafenib	Midostaurin	Sunitinib	Lestaurtinib	Tandutinib
Target	FLT3; c-KIT; VEGFR; PDGFR; RAF1	FLT3; c-KIT; PDGFRB; VEGFR	FLT3; c-KIT; KDR; PDGFR	FLT3; JAK2; TRK A	FLT3; PDGFR; c-KIT
Trial phase	II/III	III	II	III	I
FDA approved	No	Yes	No	No	No
2° Generation
Inhibitor	Quizartinib	Gilteritinib	Crenolanib	Ponatinib
Target	FLT3; c-KIT; PDGFRa	FLT3; AXL	FLT3; PDGFR	FLT3; BCR-ABL; c-KIT; FGFR1; PDGFRa
Trial phase	III	III	III	I/II
FDA approved	No	Yes	No	No

FDA: Food and Drug Administration.